Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

Locally Advanced Pancreatic Adenocarcinoma Clinical Trial

Official title:

A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04669197
• Other study ID #: HCQ NABPLAGEM-NEO 2020
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: December 1, 2020
• Est. completion date: September 30, 2024

Study information

• Verified date: August 2023
• Source: HonorHealth Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 19
• Est. completion date: September 30, 2024
• Est. primary completion date: May 23, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient has histologically or cytologically confirmed resectable, borderline resectable, or locally advanced (unresectable) PDAC (based upon Tempero et al 2016)
• Age = 18 years.
• If a female patient is of child-bearing potential, she must have a negative serum pregnancy test (=ß-hCG) documented within 72 hours of the first administration of study drug
• If sexually active, the patient and partner must agree to use contraception considered adequate and appropriate by the Investigator
• Patient must have received no prior chemotherapy or radiation therapy for PDAC
• Patients must have normal organ and marrow function
• Patient has acceptable coagulation status as indicated by an INR = 1.5 x ULN. Patients on anticoagulation can be included at the discretion of the investigator.
• Karnofsky Performance Status (KPS) of =70%.
• Have an elevated CA 19-9 (>2X ULN) in the context of normal bilirubin

Exclusion Criteria:

• Patient will be excluded from this study if any of the following criteria apply:

Evidence of metastatic disease. No metastatic disease defined as any one or more of the following; Suspicious lymphadenopathy outside of the standard surgical field (i.e. aortocaval nodes, distant abdominal nodes) or Radiographic evidence for metastatic disease in distant organs, peritoneum, or ascites

• Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.
• Known infection with HIV, hepatitis B, or hepatitis C.
• Has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
• History of allergy or hypersensitivity to the study drugs.
• Serious medical risk factors involving any of the major organ systems such that the Investigator considers it unsafe for the patient to receive an experimental research drug.
• Current, serious, clinically significant cardiac arrhythmias as determined by the investigator.
• Patient is unwilling or unable to comply with study procedures.
• Patient is enrolled in an industry sponsored clinical trial involving treatment with investigational therapy. Patients enrolled in HonorHealth sponsored research studies may be eligible to participate as long as their participation in the other research studies does not confound the data collected for this study.
• Patient with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies.
• Use of non-FDA approved cannabinoids are prohibited. Total daily usage of up to 40 mg per day of marinol is acceptable.

Exclusion Criteria for Hydroxychloroquine Expansion Cohort only:

• Prolonged QTcF > 450 ms for men and > 470 ms for women at Screening. Electrolyte imbalances (e.g. hypokalemia/hypomagnesemia/hypocalcemia) must be corrected prior to first dose of hydroxychloroquine.
• Known second or third degree atrioventricular block.
• Patient is taking a concomitant medication that has "known" risk of QT prolongation or torsdades de pointe.
• Patient has pre-existing retinopathy.
• Patient has known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds.

Related Conditions & MeSH terms

• Adenocarcinoma
• Borderline Resectable Pancreatic Adenocarcinoma
• Locally Advanced Pancreatic Adenocarcinoma
• Untreated Resectable Pancreatic Adenocarcinoma

Intervention

Drug:
• Paclitaxel protein bound
combination therapy
• Gemcitabine
combination therapy
• Cisplatin
combination therapy
• Hydroxychloroquine
combination therapy

Locations

Country	Name	City	State
United States	HonorHealth Research Institute	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
HonorHealth Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Normalization Rate of CA 19-9	Evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.	6 months
Secondary	Resectability Rate	Assess the resectability rate following neoadjuvant chemotherapy	6 months to 2 years
Secondary	Survival Rate	Assess the 2 year survival from date of study entry	2 years
Secondary	Response Rate	Assess the pathologic complete response rate and radiologic response rate	6 months to 2 years
Secondary	Incidence of Treatment-Emergent Adverse Events	Assess the Grade 3 or Grade 4 related adverse events as assessed by CTCAE Version 5.0	6 months to 2 years